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Background: SLE is clinically and immunologically heterogeneous(1).  Type I interferons (IFN-I) are pathogenic but
expression of IFN-I stimulated genes varies.  Many existing reports on clinical phenotype and IFN-I were limited by using
categorical measures of IFN-I and disease activity scores that were not organ-specific. IFN-I targeted therapies are in
development (2,3).
Objectives: To define the clinical phenotype of IFN-I mediated SLE.
Methods: 108 SLE patients and 20 age and sex matched healthy controls were studied. Activity was measured using
BILAG-2004. PBMCs were collected for gene expression analysis using TaqMan. Relative expression of 7 interferon
stimulated genes was In-transformed, normalized to healthy control and summed to derive a 7-gene IFN-I score.
Results: The most common activity was mucocutaneous and musculoskeletal, which were analysed in detail (Table 1). 
The relationship between activity and IFN-I score differed between these domains.  Overall, IFN-I scores were higher in
active mucocutaneous disease. Scores were more variable for BILAG B: this was explained by subtype of BILAG B
disease.  IFN-I score was increased in subacute and discoid forms (25.3(16.8-32.9), n=7) compared to acute forms
(18.4(4.9-31), n=15). Score was also higher in patients with anti-Ro60.  In contrast, there was no relationship between
musculoskeletal disease activity and IFN-I score.
Numbers of patients with renal, haematological and neuropsychiatric activity were limited but there was a trend to higher
IFN-I scores with disease activity.
BILAG Domain Score (n) IFN Score Median (IQR) P value vs. D+E P Value vs. E
Mucocutaneous
A (6) 27.2 (26.3-31.5) 0.027 0.005
B (22) 20.5 (9.1-32) 0.255 0.181
C (18) 30.7 (11.7-38.2) 0.025 0.042
D (46) 19.3 (3.7-28.1) NA 0.469
E (16) 14 (4.2-22.6) NA NA
D+E (62) 17.6 (3.7-27.6) NA NA
Musculoskeletal
A (6) 24.9 (5-31) 0.846 0.662
B (15) 19.8 (6.5-28.4) 0.652 0.925
C (37) 17.2 (3.5-30.7) 0.445 0.965
D (42) 24.2 (6.2-31.8) NA 0.746
E (8) 19.4 (10.8-26.3) NA NA
D+E (50) 23.5(6.2-31.4) NA NA
Conclusions: We identify a relationship between clinical presentation of SLE and IFN-I.  High IFN-I activity is linked to
anti-Ro60 and non-acute forms of skin disease. We previously reported a worse response to rituximab in this subgroup,
whilst response in musculoskeletal disease was consistently good. Measurement of B cell and interferon biomarkers may
therefore be important in the selection of the most appropriate targeted therapy for SLE.
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